Xenon Pharmaceuticals Inc. Stock News

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of ...

Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executive Vice President of Drug Discovery JP Gilbert Christopher Kenney - Chief Medical Officer Presentation Ian Mortimer Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Of...

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs target...

VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of ...

Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent efficacy support its potential in epilepsy and neuropsychiatric indications, expanding its market opportunity. Xenon's strong cash position funds operations into 2027, with possible fundraising afte...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Chief Medical Officer Darren S. Cline - Chief Commercial Officer and Member of Executive Team Ian C.

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain – Darren Cline appointed as Chief Commercial Officer to lead commercial build a...

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. fi...